Aeolus Pharmaceuticals Inc., of San Diego, appointed John Farah to its board.

AEterna Zentaris Inc., of Quebec City, appointed Jurgen Ernst vice chairman of its board.

AlgoRx Pharmaceuticals Inc., of Secaucus, N.J., and Corgentech Inc., of South San Francisco, appointed Robert Zerbe as the ninth board member for the combined company.

Allos Therapeutics Inc., of Westminster, Colo., appointed Timothy Lynch to its board.

Amarin Corp. plc, of London, appointed Tom Maher general counsel.

Anthera Pharmaceuticals Inc., of San Francisco, appointed David Thompson to its board.

Argolyn Bioscience Inc., of North Charleston, S.C., appointed Thomas Caskey to its board.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed Richard Pascoe vice president and chief commercial officer.

Athenagen Inc., of South San Francisco, appointed Henry Hsu chief medical officer, and Ken Kengatharan vice president of preclinical R&D.

BioAxone, of Montreal, appointed Patrick Tremblay vice president, R&D.

Biolex Therapeutics, of Pittsboro, N.C., appointed Glen Williams senior vice president of operations, John Elliott Humphries vice president of development and Dee Parson Grange vice president of business development.

BioMedinvest AG, of Basel, Switzerland, appointed Bert van Toor a partner.

BioMS Medical Corp., of Edmonton, Alberta, appointed Bryan McKnight to its board and chair of the audit committee, and Gordon Politeski as an adviser to its board pending his nomination as a director. In addition, Kjell Stenberg will assume the position of chief operating officer.

Cardium Therapeutics Inc., of San Diego, appointed Dennis Mulroy chief financial officer, Robert Engler chief medical adviser, Patricia Novak vice president of program development, Ted Williams vice president of manufacturing and technical operations, Jennifer Spinella vice president of regulatory affairs and Anthony Andrasfay vice president of clinical operations.

Cellerant Therapeutics Inc., of San Carlos, Calif., appointed Ramkumar Mandalam vice president of pharmaceutical operations.

ChondroGene Ltd., of Toronto, appointed Daniel Farkas vice president of clinical diagnostics.